ID   NHRF1_HUMAN             Reviewed;         358 AA.
AC   O14745; B3KY21; O43552; Q86WQ5;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   07-APR-2021, entry version 215.
DE   RecName: Full=Na(+)/H(+) exchange regulatory cofactor NHE-RF1;
DE            Short=NHERF-1;
DE   AltName: Full=Ezrin-radixin-moesin-binding phosphoprotein 50;
DE            Short=EBP50;
DE   AltName: Full=Regulatory cofactor of Na(+)/H(+) exchanger;
DE   AltName: Full=Sodium-hydrogen exchanger regulatory factor 1;
DE   AltName: Full=Solute carrier family 9 isoform A3 regulatory factor 1;
GN   Name=SLC9A3R1; Synonyms=NHERF, NHERF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 19-32 AND
RP   341-350, PHOSPHORYLATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   INTERACTION WITH EZR AND MSN.
RX   PubMed=9314537; DOI=10.1083/jcb.139.1.169;
RA   Reczek D., Berryman M., Bretscher A.;
RT   "Identification of EBP50: a PDZ-containing phosphoprotein that associates
RT   with members of the ezrin-radixin-moesin family.";
RL   J. Cell Biol. 139:169-179(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH EZR; RDX AND MSN.
RC   TISSUE=Fetal brain;
RX   PubMed=9430655; DOI=10.1074/jbc.273.3.1273;
RA   Murthy A., Gonzalez-Agosti C., Cordero E., Pinney D., Candia C.,
RA   Solomon F., Gusella J., Ramesh V.;
RT   "NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common
RT   interactor for merlin and ERM (MERM) proteins.";
RL   J. Biol. Chem. 273:1273-1276(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood, Lymph, Pancreas, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-13.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-12; 39-49 AND 89-100, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=T-cell;
RA   Bienvenut W.V., Kanor S., Tissot J.-D., Quadroni M.;
RL   Submitted (MAY-2006) to UniProtKB.
RN   [9]
RP   FUNCTION, INTERACTION WITH SLC9A3, AND TISSUE SPECIFICITY.
RX   PubMed=9096337; DOI=10.1073/pnas.94.7.3010;
RA   Yun C.H.C., Oh S., Zizak M., Steplock D., Tsao S., Tse C.-M., Weinman E.J.,
RA   Donowitz M.;
RT   "cAMP-mediated inhibition of the epithelial brush border Na+/H+ exchanger,
RT   NHE3, requires an associated regulatory protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3010-3015(1997).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH ADRB2.
RX   PubMed=10499588; DOI=10.1038/45816;
RA   Cao T.T., Deacon H.W., Reczek D., Bretscher A., von Zastrow M.;
RT   "A kinase-regulated PDZ-domain interaction controls endocytic sorting of
RT   the beta2-adrenergic receptor.";
RL   Nature 401:286-290(1999).
RN   [11]
RP   INTERACTION WITH PAG1, AND SUBCELLULAR LOCATION.
RX   PubMed=11684085; DOI=10.1016/s0014-5793(01)02955-6;
RA   Brdickova N., Brdicka T., Andera L., Spicka J., Angelisova P.,
RA   Milgram S.L., Horejsi V.;
RT   "Interaction between two adapter proteins, PAG and EBP50: a possible link
RT   between membrane rafts and actin cytoskeleton.";
RL   FEBS Lett. 507:133-136(2001).
RN   [12]
RP   INTERACTION WITH EPI64; ARHGAP17; PLCB3 AND EZR.
RX   PubMed=11285285; DOI=10.1083/jcb.153.1.191;
RA   Reczek D., Bretscher A.;
RT   "Identification of EPI64, a TBC/rabGAP domain-containing microvillar
RT   protein that binds to the first PDZ domain of EBP50 and E3KARP.";
RL   J. Cell Biol. 153:191-206(2001).
RN   [13]
RP   INTERACTION WITH RACK1.
RX   PubMed=11956211; DOI=10.1074/jbc.m201917200;
RA   Liedtke C.M., Yun C.H.C., Kyle N., Wang D.;
RT   "Protein kinase C epsilon-dependent regulation of cystic fibrosis
RT   transmembrane regulator involves binding to a receptor for activated C
RT   kinase (RACK1) and RACK1 binding to Na+/H+ exchange regulatory factor.";
RL   J. Biol. Chem. 277:22925-22933(2002).
RN   [14]
RP   INTERACTION WITH OPRK1.
RX   PubMed=12004055; DOI=10.1074/jbc.m200058200;
RA   Li J.-G., Chen C., Liu-Chen L.-Y.;
RT   "Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory
RT   factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human
RT   kappa opioid receptor by enhancing its recycling rate.";
RL   J. Biol. Chem. 277:27545-27552(2002).
RN   [15]
RP   INTERACTION WITH NOS2.
RX   PubMed=12080081; DOI=10.1074/jbc.m205764200;
RA   Glynne P.A., Darling K.E.A., Picot J., Evans T.J.;
RT   "Epithelial inducible nitric-oxide synthase is an apical EBP50-binding
RT   protein that directs vectorial nitric oxide output.";
RL   J. Biol. Chem. 277:33132-33138(2002).
RN   [16]
RP   INTERACTION WITH GNAQ.
RX   PubMed=12193606; DOI=10.1074/jbc.m207910200;
RA   Rochdi M.D., Watier V., La Madeleine C., Nakata H., Kozasa T.,
RA   Parent J.-L.;
RT   "Regulation of GTP-binding protein alpha q (Galpha q) signaling by the
RT   ezrin-radixin-moesin-binding phosphoprotein-50 (EBP50).";
RL   J. Biol. Chem. 277:40751-40759(2002).
RN   [17]
RP   INTERACTION WITH SLC4A7 AND CFTR.
RX   PubMed=12403779; DOI=10.1074/jbc.m201862200;
RA   Park M., Ko S.B.H., Choi J.Y., Muallem G., Thomas P.J., Pushkin A.,
RA   Lee M.-S., Kim J.Y., Lee M.G., Muallem S., Kurtz I.;
RT   "The cystic fibrosis transmembrane conductance regulator interacts with and
RT   regulates the activity of the HCO3- salvage transporter human Na+-HCO3-
RT   cotransport isoform 3.";
RL   J. Biol. Chem. 277:50503-50509(2002).
RN   [18]
RP   INTERACTION WITH TRPC4.
RX   PubMed=12154080;
RA   Mery L., Strauss B., Dufour J.F., Krause K.H., Hoth M.;
RT   "The PDZ-interacting domain of TRPC4 controls its localization and surface
RT   expression in HEK293 cells.";
RL   J. Cell Sci. 115:3497-3508(2002).
RN   [19]
RP   INDUCTION BY ESTROGEN.
RX   PubMed=12145337; DOI=10.1210/me.2001-0290;
RA   Ediger T.R., Park S.-E., Katzenellenbogen B.S.;
RT   "Estrogen receptor inducibility of the human Na+/H+ exchanger regulatory
RT   factor/ezrin-radixin-moesin binding protein 50 (NHE-RF/EBP50) gene
RT   involving multiple half-estrogen response elements.";
RL   Mol. Endocrinol. 16:1828-1839(2002).
RN   [20]
RP   INTERACTION WITH SLC4A7 AND ATP6V1B1.
RX   PubMed=12444018; DOI=10.1152/ajpcell.00225.2002;
RA   Pushkin A., Abuladze N., Newman D., Muronets V., Sassani P., Tatishchev S.,
RA   Kurtz I.;
RT   "The COOH termini of NBC3 and the 56-kDa H+-ATPase subunit are PDZ motifs
RT   involved in their interaction.";
RL   Am. J. Physiol. 284:C667-C673(2003).
RN   [21]
RP   INTERACTION WITH SLC26A6.
RX   PubMed=12444019; DOI=10.1152/ajpcell.00270.2002;
RA   Lohi H., Lamprecht G., Markovich D., Heil A., Kujala M., Seidler U.,
RA   Kere J.;
RT   "Isoforms of SLC26A6 mediate anion transport and have functional PDZ
RT   interaction domains.";
RL   Am. J. Physiol. 284:C769-C779(2003).
RN   [22]
RP   INTERACTION WITH CTNNB1.
RX   PubMed=12830000; DOI=10.1053/jhep.2003.50270;
RA   Shibata T., Chuma M., Kokubu A., Sakamoto M., Hirohashi S.;
RT   "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is
RT   over-expressed in hepatocellular carcinoma.";
RL   Hepatology 38:178-186(2003).
RN   [23]
RP   INTERACTION WITH CLCN3.
RX   PubMed=12471024; DOI=10.1074/jbc.m211050200;
RA   Gentzsch M., Cui L., Mengos A., Chang X.-B., Chen J.-H., Riordan J.R.;
RT   "The PDZ-binding chloride channel ClC-3B localizes to the Golgi and
RT   associates with cystic fibrosis transmembrane conductance regulator-
RT   interacting PDZ proteins.";
RL   J. Biol. Chem. 278:6440-6449(2003).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [31]
RP   INTERACTION WITH MCC.
RX   PubMed=19555689; DOI=10.1016/j.febslet.2009.06.034;
RA   Arnaud C., Sebbagh M., Nola S., Audebert S., Bidaut G., Hermant A.,
RA   Gayet O., Dusetti N.J., Ollendorff V., Santoni M.J., Borg J.P., Lecine P.;
RT   "MCC, a new interacting protein for Scrib, is required for cell migration
RT   in epithelial cells.";
RL   FEBS Lett. 583:2326-2332(2009).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-280, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-162; SER-269 AND SER-280, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [37]
RP   INTERACTION WITH SLC34A1, VARIANT NPHLOP2 ALA-68, AND CHARACTERIZATION OF
RP   VARIANT NPHLOP2 ALA-68.
RX   PubMed=22506049; DOI=10.1371/journal.pone.0034764;
RA   Courbebaisse M., Leroy C., Bakouh N., Salaun C., Beck L., Grandchamp B.,
RA   Planelles G., Hall R.A., Friedlander G., Prie D.;
RT   "A new human NHERF1 mutation decreases renal phosphate transporter NPT2a
RT   expression by a PTH-independent mechanism.";
RL   PLoS ONE 7:E34764-E34764(2012).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-46 AND SER-280, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-269; SER-280 AND SER-294, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 11-99 IN COMPLEX WITH CFTR.
RX   PubMed=11304524; DOI=10.1074/jbc.c100154200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural basis of the Na+/H+ exchanger regulatory factor PDZ1
RT   interaction with the carboxyl-terminal region of the cystic fibrosis
RT   transmembrane conductance regulator.";
RL   J. Biol. Chem. 276:19683-19686(2001).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 11-99, AND HOMODIMERIZATION.
RX   PubMed=11352585; DOI=10.1006/jmbi.2001.4634;
RA   Karthikeyan S., Leung T., Birrane G., Webster G., Ladias J.A.A.;
RT   "Crystal structure of the PDZ1 domain of human Na(+)/H(+) exchanger
RT   regulatory factor provides insights into the mechanism of carboxyl-terminal
RT   leucine recognition by class I PDZ domains.";
RL   J. Mol. Biol. 308:963-973(2001).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 11-99 IN COMPLEX WITH PDGFRA;
RP   PDGFRB OR ADRB2.
RX   PubMed=11882663; DOI=10.1074/jbc.m201507200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural determinants of the Na+/H+ exchanger regulatory factor
RT   interaction with the beta 2 adrenergic and platelet-derived growth factor
RT   receptors.";
RL   J. Biol. Chem. 277:18973-18978(2002).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.5 ANGSTROMS) OF 321-358 IN COMPLEX WITH MSX, AND
RP   MUTAGENESIS OF PHE-355 AND LEU-358.
RX   PubMed=15020681; DOI=10.1242/jcs.01038;
RA   Finnerty C.M., Chambers D., Ingraffea J., Faber H.R., Karplus P.A.,
RA   Bretscher A.;
RT   "The EBP50-moesin interaction involves a binding site regulated by direct
RT   masking on the FERM domain.";
RL   J. Cell Sci. 117:1547-1552(2004).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 331-358 IN COMPLEX WITH RDX.
RX   PubMed=16615918; DOI=10.1016/j.str.2006.01.015;
RA   Terawaki S., Maesaki R., Hakoshima T.;
RT   "Structural basis for NHERF recognition by ERM proteins.";
RL   Structure 14:777-789(2006).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 150-236.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of the 2nd PDZ domain of the human NHERF-1
RT   (SLC9A3R1).";
RL   Submitted (MAR-2007) to the PDB data bank.
RN   [48]
RP   FUNCTION IN RENAL PHOSPHATE ABSORPTION, VARIANTS NPHLOP2 VAL-110; GLN-153
RP   AND LYS-225, AND CHARACTERIZATION OF VARIANTS NPHLOP2 VAL-110; GLN-153 AND
RP   LYS-225.
RX   PubMed=18784102; DOI=10.1056/nejmoa0802836;
RA   Karim Z., Gerard B., Bakouh N., Alili R., Leroy C., Beck L., Silve C.,
RA   Planelles G., Urena-Torres P., Grandchamp B., Friedlander G., Prie D.;
RT   "NHERF1 mutations and responsiveness of renal parathyroid hormone.";
RL   N. Engl. J. Med. 359:1128-1135(2008).
CC   -!- FUNCTION: Scaffold protein that connects plasma membrane proteins with
CC       members of the ezrin/moesin/radixin family and thereby helps to link
CC       them to the actin cytoskeleton and to regulate their surface
CC       expression. Necessary for recycling of internalized ADRB2. Was first
CC       known to play a role in the regulation of the activity and subcellular
CC       location of SLC9A3. Necessary for cAMP-mediated phosphorylation and
CC       inhibition of SLC9A3. May enhance Wnt signaling. May participate in
CC       HTR4 targeting to microvilli (By similarity). Involved in the
CC       regulation of phosphate reabsorption in the renal proximal tubules.
CC       Involved in sperm capacitation. May participate in the regulation of
CC       the chloride and bicarbonate homeostasis in spermatozoa. {ECO:0000250,
CC       ECO:0000269|PubMed:10499588, ECO:0000269|PubMed:18784102,
CC       ECO:0000269|PubMed:9096337, ECO:0000269|PubMed:9430655}.
CC   -!- SUBUNIT: Homodimer, and heterodimer with SLC9A3R2. Binds the N-termini
CC       of EZR, RDX and MSN. Binds the C-termini of PDGFRA, PDGFRB, ADRB2, NOS2
CC       and CFTR. Binds ARHGAP17, EPI64, RACK1, OPRK1, GNAQ, CTNNB1 and PLCB3.
CC       Binds PDZK1 (By similarity). Interacts with CLCN3. Binds the C-terminus
CC       of PAG1. In resting T-cells, part of a PAG1-SLC9A3R1-MSN complex which
CC       is disrupted upon TCR activation. Forms a complex with CFTR and SLC4A7.
CC       Forms a complex with SLC4A7 and ATP6V1B1. Interacts with TRPC4 (via the
CC       PDZ-binding domain). Directly interacts with HTR4 (By similarity).
CC       Interacts (via the PDZ 1 domain) with PODXL (via the C-terminal PDZ-
CC       binding motif DTHL); interaction is not detected in glomerular
CC       epithelium cells. Interacts (via the PDZ 1 domain) with PODXL (via the
CC       C-terminal PDZ-binding motif DTHL); the interaction take place early in
CC       the secretory pathway and is necessary for its apical membrane sorting
CC       (By similarity). Interacts with SLC26A3 (By similarity). Interacts with
CC       MCC. Interacts with SLC34A1. Interacts (via the PDZ domains) with
CC       SLC26A6 isoform 4 and isoform 5. {ECO:0000250,
CC       ECO:0000269|PubMed:10499588, ECO:0000269|PubMed:11285285,
CC       ECO:0000269|PubMed:11304524, ECO:0000269|PubMed:11684085,
CC       ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:11956211,
CC       ECO:0000269|PubMed:12004055, ECO:0000269|PubMed:12080081,
CC       ECO:0000269|PubMed:12154080, ECO:0000269|PubMed:12193606,
CC       ECO:0000269|PubMed:12403779, ECO:0000269|PubMed:12444018,
CC       ECO:0000269|PubMed:12444019, ECO:0000269|PubMed:12471024,
CC       ECO:0000269|PubMed:12830000, ECO:0000269|PubMed:15020681,
CC       ECO:0000269|PubMed:16615918, ECO:0000269|PubMed:19555689,
CC       ECO:0000269|PubMed:22506049, ECO:0000269|PubMed:9096337,
CC       ECO:0000269|PubMed:9314537, ECO:0000269|PubMed:9430655}.
CC   -!- INTERACTION:
CC       O14745; P07550: ADRB2; NbExp=6; IntAct=EBI-349787, EBI-491169;
CC       O14745; Q92624: APPBP2; NbExp=3; IntAct=EBI-349787, EBI-743771;
CC       O14745; P13569: CFTR; NbExp=11; IntAct=EBI-349787, EBI-349854;
CC       O14745; P29762: CRABP1; NbExp=3; IntAct=EBI-349787, EBI-725950;
CC       O14745; Q9Y2H0-1: DLGAP4; NbExp=3; IntAct=EBI-349787, EBI-12000556;
CC       O14745; P15311: EZR; NbExp=6; IntAct=EBI-349787, EBI-1056902;
CC       O14745; P26038: MSN; NbExp=4; IntAct=EBI-349787, EBI-528768;
CC       O14745; P35240-1: NF2; NbExp=4; IntAct=EBI-349787, EBI-1014500;
CC       O14745; P47900: P2RY1; NbExp=2; IntAct=EBI-349787, EBI-8677223;
CC       O14745; P09619: PDGFRB; NbExp=5; IntAct=EBI-349787, EBI-641237;
CC       O14745; O60346: PHLPP1; NbExp=2; IntAct=EBI-349787, EBI-2511516;
CC       O14745; O60346-2: PHLPP1; NbExp=5; IntAct=EBI-349787, EBI-11165225;
CC       O14745; Q6ZVD8: PHLPP2; NbExp=5; IntAct=EBI-349787, EBI-2511496;
CC       O14745; P60484: PTEN; NbExp=7; IntAct=EBI-349787, EBI-696162;
CC       O14745; Q9R0W0: mGluR1a; Xeno; NbExp=2; IntAct=EBI-349787, EBI-8505383;
CC       O14745; P26043: Rdx; Xeno; NbExp=2; IntAct=EBI-349787, EBI-647737;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Apical cell membrane
CC       {ECO:0000250}. Endomembrane system; Peripheral membrane protein. Cell
CC       projection, filopodium. Cell projection, ruffle. Cell projection,
CC       microvillus. Note=Translocates from the cytoplasm to the apical cell
CC       membrane in a PODXL-dependent manner. Colocalizes with CFTR at the
CC       midpiece of sperm tail (By similarity). Colocalizes with actin in
CC       microvilli-rich apical regions of the syncytiotrophoblast. Found in
CC       microvilli, ruffling membrane and filopodia of HeLa cells. Present in
CC       lipid rafts of T-cells. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O14745-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O14745-2; Sequence=VSP_055497;
CC   -!- TISSUE SPECIFICITY: Detected in liver, kidney, pancreas, prostate,
CC       spleen, small intestine and placenta, in particular in the
CC       syncytiotrophoblast. {ECO:0000269|PubMed:9096337,
CC       ECO:0000269|PubMed:9314537}.
CC   -!- INDUCTION: By estrogen. {ECO:0000269|PubMed:12145337}.
CC   -!- PTM: Phosphorylated on serine residues. {ECO:0000269|PubMed:9314537}.
CC   -!- DISEASE: Nephrolithiasis/osteoporosis, hypophosphatemic, 2 (NPHLOP2)
CC       [MIM:612287]: A disease characterized by decreased renal phosphate
CC       absorption, renal phosphate wasting, hypophosphatemia,
CC       hyperphosphaturia, hypercalciuria, nephrolithiasis and osteoporosis.
CC       {ECO:0000269|PubMed:18784102, ECO:0000269|PubMed:22506049}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH49220.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SLC9A3R1ID46023ch17q25.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF015926; AAC52084.1; -; mRNA.
DR   EMBL; AF036241; AAC04572.1; -; mRNA.
DR   EMBL; AK128474; BAG54683.1; -; mRNA.
DR   EMBL; AC016888; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89189.1; -; Genomic_DNA.
DR   EMBL; BC001443; AAH01443.1; -; mRNA.
DR   EMBL; BC003361; AAH03361.1; -; mRNA.
DR   EMBL; BC011777; AAH11777.1; -; mRNA.
DR   EMBL; BC049220; AAH49220.1; ALT_INIT; mRNA.
DR   EMBL; BC053350; AAH53350.1; -; mRNA.
DR   CCDS; CCDS11705.1; -. [O14745-1]
DR   RefSeq; NP_004243.1; NM_004252.4. [O14745-1]
DR   PDB; 1G9O; X-ray; 1.50 A; A=11-99.
DR   PDB; 1GQ4; X-ray; 1.90 A; A=11-94.
DR   PDB; 1GQ5; X-ray; 2.20 A; A=11-94.
DR   PDB; 1I92; X-ray; 1.70 A; A=11-94.
DR   PDB; 1SGH; X-ray; 3.50 A; B=321-358.
DR   PDB; 2D10; X-ray; 2.50 A; E/F/G/H=331-358.
DR   PDB; 2JXO; NMR; -; A=150-240.
DR   PDB; 2KJD; NMR; -; A=150-270.
DR   PDB; 2KRG; NMR; -; A=150-358.
DR   PDB; 2M0T; NMR; -; A=11-120.
DR   PDB; 2M0U; NMR; -; A=11-120.
DR   PDB; 2M0V; NMR; -; A=150-270.
DR   PDB; 2OZF; X-ray; 1.50 A; A=150-235.
DR   PDB; 4JL7; X-ray; 1.16 A; A=11-95.
DR   PDB; 4LMM; X-ray; 1.10 A; A=11-94.
DR   PDB; 4MPA; X-ray; 1.10 A; A=11-94.
DR   PDB; 4N6X; X-ray; 1.05 A; A=11-94.
DR   PDB; 4PQW; X-ray; 1.47 A; A=11-94.
DR   PDB; 4Q3H; X-ray; 1.44 A; A/B=150-234.
DR   PDB; 6RQR; X-ray; 2.20 A; A/B=150-269.
DR   PDBsum; 1G9O; -.
DR   PDBsum; 1GQ4; -.
DR   PDBsum; 1GQ5; -.
DR   PDBsum; 1I92; -.
DR   PDBsum; 1SGH; -.
DR   PDBsum; 2D10; -.
DR   PDBsum; 2JXO; -.
DR   PDBsum; 2KJD; -.
DR   PDBsum; 2KRG; -.
DR   PDBsum; 2M0T; -.
DR   PDBsum; 2M0U; -.
DR   PDBsum; 2M0V; -.
DR   PDBsum; 2OZF; -.
DR   PDBsum; 4JL7; -.
DR   PDBsum; 4LMM; -.
DR   PDBsum; 4MPA; -.
DR   PDBsum; 4N6X; -.
DR   PDBsum; 4PQW; -.
DR   PDBsum; 4Q3H; -.
DR   PDBsum; 6RQR; -.
DR   SMR; O14745; -.
DR   BioGRID; 114769; 125.
DR   CORUM; O14745; -.
DR   DIP; DIP-29092N; -.
DR   ELM; O14745; -.
DR   IntAct; O14745; 40.
DR   MINT; O14745; -.
DR   STRING; 9606.ENSP00000262613; -.
DR   TCDB; 8.A.24.1.1; the ezrin/radixin/moesin-binding phosphoprotein 50 (ebp50) family.
DR   iPTMnet; O14745; -.
DR   PhosphoSitePlus; O14745; -.
DR   BioMuta; SLC9A3R1; -.
DR   CPTAC; CPTAC-588; -.
DR   CPTAC; CPTAC-589; -.
DR   EPD; O14745; -.
DR   jPOST; O14745; -.
DR   MassIVE; O14745; -.
DR   MaxQB; O14745; -.
DR   PaxDb; O14745; -.
DR   PeptideAtlas; O14745; -.
DR   PRIDE; O14745; -.
DR   ProteomicsDB; 48202; -. [O14745-1]
DR   Antibodypedia; 1525; 343 antibodies.
DR   Ensembl; ENST00000262613; ENSP00000262613; ENSG00000109062. [O14745-1]
DR   Ensembl; ENST00000413388; ENSP00000464982; ENSG00000109062. [O14745-2]
DR   GeneID; 9368; -.
DR   KEGG; hsa:9368; -.
DR   UCSC; uc002jlo.5; human. [O14745-1]
DR   CTD; 9368; -.
DR   DisGeNET; 9368; -.
DR   GeneCards; SLC9A3R1; -.
DR   HGNC; HGNC:11075; SLC9A3R1.
DR   HPA; ENSG00000109062; Low tissue specificity.
DR   MalaCards; SLC9A3R1; -.
DR   MIM; 604990; gene.
DR   MIM; 612287; phenotype.
DR   neXtProt; NX_O14745; -.
DR   OpenTargets; ENSG00000109062; -.
DR   Orphanet; 244305; Dominant hypophosphatemia with nephrolithiasis or osteoporosis.
DR   PharmGKB; PA35931; -.
DR   VEuPathDB; HostDB:ENSG00000109062.9; -.
DR   eggNOG; KOG3528; Eukaryota.
DR   GeneTree; ENSGT00950000182849; -.
DR   HOGENOM; CLU_038627_1_0_1; -.
DR   InParanoid; O14745; -.
DR   OMA; QPKDRIV; -.
DR   OrthoDB; 880632at2759; -.
DR   PhylomeDB; O14745; -.
DR   TreeFam; TF350449; -.
DR   PathwayCommons; O14745; -.
DR   SignaLink; O14745; -.
DR   SIGNOR; O14745; -.
DR   BioGRID-ORCS; 9368; 9 hits in 1003 CRISPR screens.
DR   ChiTaRS; SLC9A3R1; human.
DR   EvolutionaryTrace; O14745; -.
DR   GeneWiki; Sodium-hydrogen_antiporter_3_regulator_1; -.
DR   GenomeRNAi; 9368; -.
DR   Pharos; O14745; Tbio.
DR   PRO; PR:O14745; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; O14745; protein.
DR   Bgee; ENSG00000109062; Expressed in esophagus mucosa and 232 other tissues.
DR   ExpressionAtlas; O14745; baseline and differential.
DR   Genevisible; O14745; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:ProtInc.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0071944; C:cell periphery; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0031528; C:microvillus membrane; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098797; C:plasma membrane protein complex; ISS:ARUK-UCL.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0097225; C:sperm midpiece; ISS:UniProtKB.
DR   GO; GO:0032426; C:stereocilium tip; IEA:Ensembl.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0031698; F:beta-2 adrenergic receptor binding; IPI:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0017081; F:chloride channel regulator activity; IDA:UniProtKB.
DR   GO; GO:0050780; F:dopamine receptor binding; IEA:Ensembl.
DR   GO; GO:0015185; F:gamma-aminobutyric acid transmembrane transporter activity; IEA:Ensembl.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0045159; F:myosin II binding; IEA:Ensembl.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IEA:Ensembl.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0043495; F:protein-membrane adaptor activity; IBA:GO_Central.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0031799; F:type 2 metabotropic glutamate receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0031800; F:type 3 metabotropic glutamate receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0060088; P:auditory receptor cell stereocilium organization; IEA:Ensembl.
DR   GO; GO:0032782; P:bile acid secretion; ISS:UniProtKB.
DR   GO; GO:0030643; P:cellular phosphate ion homeostasis; IEA:Ensembl.
DR   GO; GO:0090660; P:cerebrospinal fluid circulation; ISS:ARUK-UCL.
DR   GO; GO:0044782; P:cilium organization; ISS:ARUK-UCL.
DR   GO; GO:0045198; P:establishment of epithelial cell apical/basal polarity; IMP:UniProtKB.
DR   GO; GO:0051683; P:establishment of Golgi localization; IMP:UniProtKB.
DR   GO; GO:0051939; P:gamma-aminobutyric acid import; ISS:ARUK-UCL.
DR   GO; GO:0022612; P:gland morphogenesis; IMP:UniProtKB.
DR   GO; GO:0034635; P:glutathione transport; ISS:UniProtKB.
DR   GO; GO:0098739; P:import across plasma membrane; ISS:ARUK-UCL.
DR   GO; GO:0045199; P:maintenance of epithelial cell apical/basal polarity; IMP:ARUK-UCL.
DR   GO; GO:0030033; P:microvillus assembly; IMP:UniProtKB.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; NAS:ARUK-UCL.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0014067; P:negative regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0010642; P:negative regulation of platelet-derived growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0032416; P:negative regulation of sodium:proton antiporter activity; IEA:Ensembl.
DR   GO; GO:0007097; P:nuclear migration; IMP:UniProtKB.
DR   GO; GO:0060158; P:phospholipase C-activating dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007009; P:plasma membrane organization; ISS:ARUK-UCL.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0034767; P:positive regulation of ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; TAS:ProtInc.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0008361; P:regulation of cell size; IMP:UniProtKB.
DR   GO; GO:0044062; P:regulation of excretion; IEA:Ensembl.
DR   GO; GO:0045859; P:regulation of protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0032415; P:regulation of sodium:proton antiporter activity; NAS:UniProtKB.
DR   GO; GO:0070293; P:renal absorption; ISS:UniProtKB.
DR   GO; GO:0097291; P:renal phosphate ion absorption; IMP:UniProtKB.
DR   GO; GO:0003096; P:renal sodium ion transport; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   DisProt; DP02000; -.
DR   Gene3D; 2.30.42.10; -; 2.
DR   IDEAL; IID00134; -.
DR   InterPro; IPR015098; EBP50_C-term.
DR   InterPro; IPR031199; NHERF-1.
DR   InterPro; IPR017300; NHERF-1/NHERF-2.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR041489; PDZ_6.
DR   InterPro; IPR036034; PDZ_sf.
DR   PANTHER; PTHR14191:SF7; PTHR14191:SF7; 1.
DR   Pfam; PF09007; EBP50_C; 1.
DR   Pfam; PF00595; PDZ; 1.
DR   Pfam; PF17820; PDZ_6; 1.
DR   PIRSF; PIRSF037866; EBP50; 1.
DR   SMART; SM00228; PDZ; 2.
DR   SUPFAM; SSF50156; SSF50156; 2.
DR   PROSITE; PS50106; PDZ; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Cell projection; Cytoplasm; Direct protein sequencing; Disease variant;
KW   Membrane; Phosphoprotein; Reference proteome; Repeat;
KW   Wnt signaling pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801, ECO:0000269|Ref.8,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..358
FT                   /note="Na(+)/H(+) exchange regulatory cofactor NHE-RF1"
FT                   /id="PRO_0000096799"
FT   DOMAIN          14..94
FT                   /note="PDZ 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          154..234
FT                   /note="PDZ 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         269
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         280
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         290
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q28619"
FT   MOD_RES         291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70441"
FT   MOD_RES         293
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P70441"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70441"
FT   MOD_RES         302
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70441"
FT   VAR_SEQ         1..156
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055497"
FT   VARIANT         68
FT                   /note="E -> A (in NPHLOP2; impairs the interaction with
FT                   SLC34A1; causes a reduction of SLC34A1 amount on cell
FT                   membrane and affects SLC34A1-dependent phosphate uptake;
FT                   dbSNP:rs139622189)"
FT                   /evidence="ECO:0000269|PubMed:22506049"
FT                   /id="VAR_067661"
FT   VARIANT         110
FT                   /note="L -> V (in NPHLOP2; the mutant expressed in cultured
FT                   renal cells increases the generation of cyclic AMP (cAMP)
FT                   by parathyroid hormone (PTH) and inhibits phosphate
FT                   transport; dbSNP:rs35910969)"
FT                   /evidence="ECO:0000269|PubMed:18784102"
FT                   /id="VAR_034899"
FT   VARIANT         153
FT                   /note="R -> Q (in NPHLOP2; the mutant expressed in cultured
FT                   renal cells increases the generation of cAMP by PTH and
FT                   inhibits phosphate transport; dbSNP:rs41282065)"
FT                   /evidence="ECO:0000269|PubMed:18784102"
FT                   /id="VAR_048021"
FT   VARIANT         225
FT                   /note="E -> K (in NPHLOP2; the mutant expressed in cultured
FT                   renal cells increases the generation of cAMP by PTH and
FT                   inhibits phosphate transport; dbSNP:rs119486097)"
FT                   /evidence="ECO:0000269|PubMed:18784102"
FT                   /id="VAR_048022"
FT   MUTAGEN         355
FT                   /note="F->R: Loss of MSX binding."
FT                   /evidence="ECO:0000269|PubMed:15020681"
FT   MUTAGEN         358
FT                   /note="Missing: Reduces MSX binding."
FT                   /evidence="ECO:0000269|PubMed:15020681"
FT   STRAND          13..18
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   STRAND          23..25
FT                   /evidence="ECO:0007744|PDB:4PQW"
FT   STRAND          27..30
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   STRAND          32..40
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   HELIX           47..50
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   STRAND          58..62
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   HELIX           72..81
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   STRAND          82..91
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   TURN            93..95
FT                   /evidence="ECO:0007744|PDB:4N6X"
FT   TURN            101..103
FT                   /evidence="ECO:0007744|PDB:2M0T"
FT   TURN            106..108
FT                   /evidence="ECO:0007744|PDB:2M0T"
FT   HELIX           109..112
FT                   /evidence="ECO:0007744|PDB:2M0T"
FT   STRAND          115..118
FT                   /evidence="ECO:0007744|PDB:2M0T"
FT   STRAND          153..158
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   TURN            160..162
FT                   /evidence="ECO:0007744|PDB:2JXO"
FT   STRAND          166..170
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   STRAND          172..182
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   STRAND          184..186
FT                   /evidence="ECO:0007744|PDB:2M0V"
FT   HELIX           187..190
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   STRAND          198..202
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   HELIX           212..221
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   TURN            222..224
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   STRAND          225..231
FT                   /evidence="ECO:0007744|PDB:4Q3H"
FT   HELIX           233..242
FT                   /evidence="ECO:0007744|PDB:6RQR"
FT   HELIX           249..252
FT                   /evidence="ECO:0007744|PDB:6RQR"
FT   HELIX           261..265
FT                   /evidence="ECO:0007744|PDB:6RQR"
FT   STRAND          286..289
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   HELIX           297..299
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   STRAND          300..302
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   STRAND          313..315
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   HELIX           323..328
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   HELIX           329..333
FT                   /evidence="ECO:0007744|PDB:2KRG"
FT   HELIX           348..355
FT                   /evidence="ECO:0007744|PDB:2D10"
SQ   SEQUENCE   358 AA;  38868 MW;  E33AF87016D37A65 CRC64;
     MSADAAAGAP LPRLCCLEKG PNGYGFHLHG EKGKLGQYIR LVEPGSPAEK AGLLAGDRLV
     EVNGENVEKE THQQVVSRIR AALNAVRLLV VDPETDEQLQ KLGVQVREEL LRAQEAPGQA
     EPPAAAEVQG AGNENEPREA DKSHPEQREL RPRLCTMKKG PSGYGFNLHS DKSKPGQFIR
     SVDPDSPAEA SGLRAQDRIV EVNGVCMEGK QHGDVVSAIR AGGDETKLLV VDRETDEFFK
     KCRVIPSQEH LNGPLPVPFT NGEIQKENSR EALAEAALES PRPALVRSAS SDTSEELNSQ
     DSPPKQDSTA PSSTSSSDPI LDFNISLAMA KERAHQKRSS KRAPQMDWSK KNELFSNL
//
